Thursday November 26 2009 | Biotechnology feed | All feeds

Semafore Pharmaceuticals, Inc.

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

BioPortfolio no longer holds the full text of this article, it is however likley to be available via the below links:

Drugs.com - Clinical Trial Results Archive May 2009 May 19, Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting ...
http://www.drugs.com/clinical_trials_archive/May-2009.html...
Archive News & Video for Tuesday, 19 May, 2009 | Reuters.com 19 May 2009 ... Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, ... 07:00 AM EDT. Harbin Electric Expands into Linear Motor ...
http://www.reuters.com/resources/archive/us/20090519.html...

Browse other news from this organisation: Semafore Pharmaceuticals, Inc.

(If any, Generated Automatically)

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.